WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) ...
Vanda Pharmaceuticals (NASDAQ:VNDA) is alleging that members of the U.S. FDA "have committed to delay" its request for a hearing to discuss the agency's issuing of a Complete Response Letter in ...
Vanda Pharmaceuticals (NASDAQ:VNDA) saw its shares rise more than 5% in premarket trading Monday following a favorable court ruling related to its sleep disorder treatment. The company reported that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results